February 28, 2017 / 11:35 AM / 5 months ago

BRIEF-Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy

1 Min Read

Feb 28 (Reuters) - Achillion Pharmaceuticals Inc

* Achillion Pharmaceuticals to support a natural history study of C3 glomerulopathy, a rare renal disorder, conducted by experts at Imperial College London Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below